To identify the upstream signaling pathways perturbed by dehydrocrenatidine, the phosphorylation status of ERK1/2, p38, JNK1/2, and AKT was determined in dehydrocrenatidine-treated liver cancer cells. The gene discussed is MAPK3; the disease is liver cancer.